Three Biotechs Deliver Catalysts to Watch

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The company's broader drug-product development plan may proceed in parallel with planned late-stage clinical development provided supporting data are submitted.

  60% confidence

• Ernexa remains on schedule to submit its IND application for ERNA-101 during the third quarter of 2026, with a first-in-human Phase 1 clinical trial anticipated during the fourth quarter of 2026.

  60% confidence

• NeOnc's proposed CMC strategy appears reasonable, while additional manufacturing, formulation, stability, and bioavailability work is needed as the company transitions from capsule to tablet formulation.

  60% confidence

• The FDA feedback does not represent approval of NEO212 or agreement on future registrational trial design, and future FDA interactions will depend upon forthcoming clinical data, with regulatory decisions remaining subject to independent FDA review.

  60% confidence

• VivoSim remains eligible for up to an additional $45 million in future milestone payments from Eli Lilly if regulatory and commercial objectives for the IBD program are successfully achieved.

  60% confidence

• Topline Phase 2a data from the fully enrolled NEO100-01 study is expected by the end of July 2026.

  60% confidence

• VivoSim projects more than 500% revenue growth during Fiscal Year 2027, driven by increasing pharmaceutical adoption of its NAMs human tissue testing platform.

  60% confidence

Cited in these Via News reports

• Biotech Grows Up: A Phase 3 Win, a Profitable Incyte and Royalty Income, While the Early Pipeline and AI Drugs Still Have to Prove Themselves →